Novonesis Valuation
Is NSIS B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NSIS B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NSIS B (DKK390.1) is trading below our estimate of fair value (DKK413.11)
Significantly Below Fair Value: NSIS B is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NSIS B?
Key metric: As NSIS B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is NSIS B's PE Ratio? | |
|---|---|
| PE Ratio | 85.9x |
| Earnings | €282.79m |
| Market Cap | €24.30b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.5x |
| Enterprise Value/EBITDA | 39x |
| PEG Ratio | 80.4x |
Price to Earnings Ratio vs Peers
How does NSIS B's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29x | ||
ASIANPAINT Asian Paints | 52.1x | 8.6% | ₹2.4t |
PPG PPG Industries | 19.2x | 7.8% | US$28.4b |
600309 Wanhua Chemical Group | 15.8x | 19.5% | CN¥239.8b |
RPM RPM International | 28.8x | 10.9% | US$17.4b |
NSIS B Novonesis | 85.9x | 1.1% | DKK 181.2b |
Price-To-Earnings vs Peers: NSIS B is expensive based on its Price-To-Earnings Ratio (85.9x) compared to the peer average (29x).
Price to Earnings Ratio vs Industry
How does NSIS B's PE Ratio compare vs other companies in the European Chemicals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: NSIS B is expensive based on its Price-To-Earnings Ratio (85.9x) compared to the European Chemicals industry average (17.9x).
Price to Earnings Ratio vs Fair Ratio
What is NSIS B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 85.9x |
| Fair PE Ratio | 31.3x |
Price-To-Earnings vs Fair Ratio: NSIS B is expensive based on its Price-To-Earnings Ratio (85.9x) compared to the estimated Fair Price-To-Earnings Ratio (31.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | DKK 390.10 | DKK 486.88 +24.8% | 10.9% | DKK 586.00 | DKK 364.00 | n/a | 16 |
| Nov ’25 | DKK 432.10 | DKK 488.00 +12.9% | 11.1% | DKK 560.00 | DKK 360.00 | n/a | 15 |
| Oct ’25 | DKK 473.40 | DKK 487.50 +3.0% | 11.0% | DKK 560.00 | DKK 360.00 | n/a | 16 |
| Sep ’25 | DKK 468.00 | DKK 464.99 -0.6% | 11.1% | DKK 540.00 | DKK 360.00 | n/a | 16 |
| Aug ’25 | DKK 435.80 | DKK 458.43 +5.2% | 10.6% | DKK 540.00 | DKK 360.00 | n/a | 16 |
| Jul ’25 | DKK 422.40 | DKK 449.81 +6.5% | 10.7% | DKK 540.00 | DKK 350.00 | n/a | 16 |
| Jun ’25 | DKK 408.60 | DKK 437.35 +7.0% | 9.1% | DKK 500.00 | DKK 350.00 | n/a | 14 |
| May ’25 | DKK 383.60 | DKK 430.86 +12.3% | 9.2% | DKK 500.00 | DKK 350.00 | n/a | 14 |
| Apr ’25 | DKK 405.20 | DKK 419.78 +3.6% | 9.6% | DKK 500.00 | DKK 340.00 | n/a | 14 |
| Mar ’25 | DKK 392.20 | DKK 408.29 +4.1% | 8.5% | DKK 460.00 | DKK 326.00 | n/a | 14 |
| Feb ’25 | DKK 371.60 | DKK 397.38 +6.9% | 8.2% | DKK 450.00 | DKK 326.00 | n/a | 13 |
| Jan ’25 | DKK 371.10 | DKK 386.62 +4.2% | 8.1% | DKK 430.00 | DKK 326.00 | n/a | 13 |
| Dec ’24 | DKK 356.10 | DKK 376.54 +5.7% | 9.0% | DKK 430.00 | DKK 326.00 | n/a | 13 |
| Nov ’24 | DKK 316.40 | DKK 361.77 +14.3% | 11.9% | DKK 430.00 | DKK 275.00 | DKK 432.10 | 13 |
| Oct ’24 | DKK 284.70 | DKK 374.00 +31.4% | 12.6% | DKK 460.00 | DKK 275.00 | DKK 473.40 | 13 |
| Sep ’24 | DKK 297.40 | DKK 373.36 +25.5% | 11.4% | DKK 460.00 | DKK 300.00 | DKK 468.00 | 14 |
| Aug ’24 | DKK 336.60 | DKK 385.64 +14.6% | 11.3% | DKK 460.00 | DKK 300.00 | DKK 435.80 | 14 |
| Jul ’24 | DKK 317.90 | DKK 393.50 +23.8% | 13.4% | DKK 520.00 | DKK 300.00 | DKK 422.40 | 14 |
| Jun ’24 | DKK 337.80 | DKK 396.36 +17.3% | 12.6% | DKK 520.00 | DKK 320.00 | DKK 408.60 | 14 |
| May ’24 | DKK 354.00 | DKK 395.64 +11.8% | 12.2% | DKK 510.00 | DKK 320.00 | DKK 383.60 | 14 |
| Apr ’24 | DKK 350.90 | DKK 387.64 +10.5% | 12.8% | DKK 510.00 | DKK 320.00 | DKK 405.20 | 14 |
| Mar ’24 | DKK 341.40 | DKK 391.93 +14.8% | 13.5% | DKK 520.00 | DKK 320.00 | DKK 392.20 | 14 |
| Feb ’24 | DKK 358.00 | DKK 393.71 +10.0% | 13.8% | DKK 520.00 | DKK 320.00 | DKK 371.60 | 14 |
| Jan ’24 | DKK 351.90 | DKK 415.80 +18.2% | 13.4% | DKK 520.00 | DKK 330.00 | DKK 371.10 | 15 |
| Dec ’23 | DKK 425.40 | DKK 410.19 -3.6% | 15.1% | DKK 540.00 | DKK 330.00 | DKK 356.10 | 16 |
| Nov ’23 | DKK 390.30 | DKK 423.94 +8.6% | 14.8% | DKK 540.00 | DKK 330.00 | DKK 316.40 | 16 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.